Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HighCycle: Acetazolamide Effect on Plasma Volume at High Altitude
NCT07118462Phase 4
Key facts
- Status
- Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Countries
- 1
- Sponsor
- EXALT
- Modality
- Small Molecules
- Drugs
- acetazolamide
- Conditions
- acute mountain sickness (AMS)
01
Overview
Phase 4, randomised, double-blind trial in acute mountain sickness (AMS) comparing Acetazolamide with Placebo (2 arms). Primary endpoint: Plasma volume at Day 3. Started Jul 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Acetazolamide
Acetazolamide 250 mg/day (125 mg BID)
Placebo
Placebo capsules (BID)
03
Endpoints
Primary
Plasma volume
Secondary
Plasma volume : sex-related difference
Plasma volume : AMS-related difference
Hormones
Arterial blood gases
Beyond the preview
Go deeper on NCT07118462.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118462.